180 Life Sciences Price/Book
What is the Price/Book of 180 Life Sciences?
The Price/Book of 180 Life Sciences Corp. is -91.95
What is the definition of Price/Book?
Price to book ratio represents the ratio between a company’s stock value and the book value per share.
mrq (most recent quarter)
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Price/Book of companies in the Health Care sector on NASDAQ compared to 180 Life Sciences
What does 180 Life Sciences do?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Companies with price/book similar to 180 Life Sciences
- Tuscan has Price/Book of -99.44
- Ravindra has Price/Book of -94.72
- Napier Ventures has Price/Book of -94.14
- Masco has Price/Book of -94.03
- Ventoux CCM Acquisition has Price/Book of -93.93
- EncounterCare Solutions has Price/Book of -92.78
- 180 Life Sciences has Price/Book of -91.95
- Fortinet Inc has Price/Book of -91.49
- DP Eurasia N.V has Price/Book of -91.24
- Candy Club has Price/Book of -88.34
- Trend Innovations has Price/Book of -88.03
- New West Services has Price/Book of -87.83
- Largo Physical Vanadium Corp has Price/Book of -87.15